NIKKEI 225
38,703.51 +213.34 (+0.55%) HANG SENG
18,476.80 +51.84 (+0.28%) CRUDE OIL
75.67 +0.12 (+0.16%) GOLD FUTURES
2,395.20 +4.30 (+0.18%) DOW
38,886.17 +78.84 (+0.20%) Bitcoin GBP
55,282.31 -375.24 (-0.67%)
Cytosorbents Corporation (HQE1.F)
| Previous close | 0.7860 |
| Open | 0.8250 |
| Bid | 0.7850 x 160000 |
| Ask | 0.8280 x 150000 |
| Day's range | 0.8250 - 0.8250 |
| 52-week range | 0.7000 - 3.6000 |
| Volume | |
| Avg. volume | 7 |
| Market cap | 27.122M |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it will host its 2024 Virtual Annual Stockholders Meeting tomorrow, June 6, 2024 at 10 AM EDT. CytoSorbents Corporation Virtual Annual Stockholder Meeting When: Thursday, June 6, 2024, at 10:00 ΑΜ EDTWebcast: www.virtualshareholdermeeting.com/CTSO2024 Requirement
- GlobeNewswire
CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract
PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the recent data presentation entitled “Early CABG with Intraoperative Haemoadsorption in Patients on Ticagrelor: The Safe and Timely Antithrombotic Removal (STAR) Registry,” at the international EuroPCR 2024 conference
- GlobeNewswire
CytoSorbents Reports First Quarter 2024 Results
Product Sales up a robust 14% over prior year, and a significant 22% sequentiallyWe believe the STAR-T data presented at AATS support a favorable benefit-to-risk profile of DrugSorb-ATR in coronary artery bypass graft (CABG) patients On track for U.S. Food and Drug Administration (FDA) De Novo and Health Canada submissions for DrugSorb®-ATR in Q3 2024 PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in critical care and cardiac surgery blood pu
